Celularity Inc
Celularity Inc (CELU) Option Chain
Read more
Tracking the CELU option chain helps you see every strike and expiry on Celularity Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CELU options activity at a glance. Use our scanner to monitor the CELU option chain in real time and filter for the trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CELU stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CELU options are being actively traded, and where they are not.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 0.00 | 0 | 0 | 0.62 | 0.13 | — | 0.75 | 0.50 | -20.63 | — | 0.75 | 0.00 | 0.75 | 0 | 1 | 100.00 |
| 100.00 | 1 | 0 | 0.30 | 0.00 | — | 0.30 | 1.00 | +58.73 | — | 0.75 | 0.37 | 0.38 | 0 | 18 | 0.00 |
| 100.00 | 3 | 0 | 0.05 | 0.00 | — | 0.05 | 1.50 | +138.10 | 0.40 | 1.15 | 0.87 | -0.09 | 0 | 891 | 0.00 |
| 100.00 | 10 | 0 | 0.75 | 0.00 | — | 0.75 | 2.00 | +217.46 | 0.90 | 1.65 | 1.37 | -0.10 | 0 | 2 | 0.00 |
| 100.00 | 644 | 0 | 0.05 | 0.00 | — | 0.05 | 2.50 | +296.83 | 1.40 | 2.15 | 1.87 | -0.10 | 0 | 31 | 0.00 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank0.40% Low
- Market cap (M$)20
- 52 weeks high-75.29%
- 52 weeks low12.50%
- Analyst recommendationBuy
2.00 - Target price$6.00
852.38% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-10-20
- P/E—
- Future P/E—
- EPS (ttm)-1.68
- EPS growth next 5 years—
As of Nov 13, 2026